mibefradil has been researched along with Astrocytoma, Grade IV in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bigner, DD; Friedman, HS; Gray, LA; Keir, ST; Reardon, DA | 1 |
| Kowalski, L; Popp, B; Schlesinger, D; Sheehan, JP; Xu, Z | 1 |
| Augustin, E; Brautigan, DL; Dziegielewska, B; Dziegielewski, J; Gray, LS; Hosing, AS; Larner, JM; Valerie, NC | 1 |
3 other study(ies) available for mibefradil and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Glioblastoma; Humans; Kaplan-Meier Estimate; Mibefradil; Mice; Neoplasm Transplantation; Skin Neoplasms; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Inhibition of glioblastoma and enhancement of survival via the use of mibefradil in conjunction with radiosurgery.
Topics: Animals; Brain Neoplasms; Calcium Channel Blockers; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Glioblastoma; Magnetic Resonance Imaging; Mibefradil; Proportional Hazards Models; Radiosurgery; Rats; Rats, Sprague-Dawley; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Brain Neoplasms; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Survival; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 2; Mibefradil; Multiprotein Complexes; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2013 |